Vitalex Health review

Vitalex offers a clinician-mediated compounded medication pathway with advertised starting prices. Its unresolved cancellation and privacy language makes it a cautious comparison for readers willing to obtain the actual subscription terms before authorizing charges.

Vitalex Health, LLC describes a technology and concierge platform connecting patients with independent providers and compounding pharmacies. Although its about page uses practice-oriented wording, the footer and legal terms say the platform does not practice medicine, prescribe or dispense. Those responsibilities belong to the clinical and pharmacy teams.

The public offer does not identify the treating medical group, individual prescriber or dispensing pharmacy. Claims about board-certified providers and licensed pharmacies are platform representations, not independent verification. Ask who will actually treat you and fill the prescription before relying on those broad descriptions.

The catalog includes semaglutide and tirzepatide injections, a separate oral GLP-1 option and microdose program. A separately advertised NAD+ prescription offer does not establish a complete catalog of available therapies or a common price structure across services.

Vitalex describes provider review before treatment, with prescriptions dependent on individual clinical decisions. The semaglutide and tirzepatide pages describe their own candidate criteria and exclusions; those are service statements rather than independent medical guidance or guaranteed eligibility. The microdose program addresses different goals and should not automatically inherit the same criteria.

Nationwide marketing is qualified by a FAQ limiting service to states where the program operates. Terms require adults eighteen or older, or a higher applicable age of majority, and a physical location matching the shipping state. A complete treatment-specific state roster is not established. Confirm your location and proposed prescription rather than assuming every advertised option is available everywhere.

The insurance arrangement is unclear. Health-plan references in privacy material do not prove insurance acceptance or reimbursement. Ask whether any part of the actual order is billable to insurance and what you will owe directly, including tests and supplies.

Privacy promises need careful scope. The product FAQ says information is shared only with the provider and pharmacy and uses broad never-sold-or-shared wording. The website privacy and California notices permit service-provider, advertising and analytics disclosures, including categories that may count as sale or sharing under California law. The HIPAA notice separately says protected health information is not sold or used for marketing without authorization. Those are different scopes, not one unconditional no-sharing guarantee.

The terms say the platform is not a HIPAA covered entity and may act as a business associate in some circumstances. The HIPAA notice describes voluntary substantial compliance. These statements qualify broad compliance marketing and do not establish an independent security or compliance assessment.

The catalog advertises starting monthly prices of $149 for semaglutide injection, $169 for tirzepatide injection, $98.99 for the GLP-1 microdose option and $189 for GLP-1 oral. NAD+ has a separate $159 starting headline. The homepage says price is confirmed after provider review. These figures therefore do not establish a final all-dose charge or a universal monthly minimum.

Program FAQs advertise flat-rate pricing without a consultation fee or dose-change surcharge. The terms describe subscriptions bundling the pharmacy drug charge, medical-group/provider fee and platform access, with product-specific amounts and intervals disclosed at checkout. Taxes and other fees may be separate. Exact laboratory and supply inclusions remain unclear; request an itemized quote for the formulation and dose actually prescribed.

For recurring monthly orders, the terms authorize charging immediately and every thirty days thereafter, with notice five to seven days before a charge. The homepage says unapproved patients are not charged, while the terms describe a refund if the provider declines. These statements do not settle whether an initial authorization, hold or captured payment occurs before approval. Monthly billing also does not establish exact medication quantity, shipment cadence or a future renewal price.

Cancellation deadlines conflict. Semaglutide, tirzepatide and microdose FAQs require thirty days’ notice before the next billing cycle, while the terms allow auto-refill cancellation up to forty-eight hours before monthly processing. Obtain the deadline that will govern your subscription in writing before authorizing recurring payments.

An initial prescription order has a separate rule: the terms permit cancellation within twenty-four hours only if the provider network has not received it, and say it cannot be canceled after that window. Medication cannot be returned or exchanged after dispensing or delivery. Other clauses allow refund exceptions for unshipped orders, prescriber decline and wrong, damaged or unsafe products. Product FAQs instead describe visits and processed prescriptions as nonrefundable once service or processing begins.

These overlapping cutoffs do not establish a general money-back promise. Stopping future refills is different from canceling an order already placed. Wrong or damaged items should be reported within forty-eight hours with the requested evidence; confirm the remedy and timing as well as the subscription’s cancellation status.

Semaglutide is described as a weekly injection, and the catalog also identifies tirzepatide injections. The program says medicines are compounded when clinically appropriate and are not FDA approved. Exact concentration, dose, additives, quantity and pharmacy assignment are unspecified. Marketing comparisons with branded trials do not establish equivalent outcomes for these compounded prescriptions.

The daily oral GLP-1 listing does not identify its molecule or exact dosage form. The microdose offer likewise leaves the specific drug, dose and route unclear. Neither should be relabeled as semaglutide tablets or a particular low-dose prescription without clarification. NAD+ has provider-set route, dose and frequency; its separate listing does not establish an injection route.